WO2001016182A3 - POLYPEPTIDES THAT BIND HIV gp120 AND RELATED NUCLEIC ACIDS, ANTIBODIES, COMPOSITIONS, AND METHODS OF USE - Google Patents

POLYPEPTIDES THAT BIND HIV gp120 AND RELATED NUCLEIC ACIDS, ANTIBODIES, COMPOSITIONS, AND METHODS OF USE Download PDF

Info

Publication number
WO2001016182A3
WO2001016182A3 PCT/US2000/023505 US0023505W WO0116182A3 WO 2001016182 A3 WO2001016182 A3 WO 2001016182A3 US 0023505 W US0023505 W US 0023505W WO 0116182 A3 WO0116182 A3 WO 0116182A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
hiv
polypeptides
antibodies
compositions
Prior art date
Application number
PCT/US2000/023505
Other languages
French (fr)
Other versions
WO2001016182A2 (en
Inventor
Carl Saxinger
Original Assignee
Us Health
Carl Saxinger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health, Carl Saxinger filed Critical Us Health
Priority to AU69410/00A priority Critical patent/AU6941000A/en
Publication of WO2001016182A2 publication Critical patent/WO2001016182A2/en
Priority to US10/084,813 priority patent/US7304127B2/en
Publication of WO2001016182A3 publication Critical patent/WO2001016182A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/162—HIV-1, HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, DC4-Binding site

Abstract

The present invention provides, among other things, a polypeptide that binds with the gp120 envelope protein of HIV, in particular HIV-1, under physiological conditions, a nucleic acid that encodes such a polypeptide and can be expressed in a cell, a composition comprising such a polypeptide or nucleic acid or an antibody and a carrier therefor, a composition comprising a solid support matrix to which is attached an above-described polypeptide or an anti-antibody to a specified polypeptide sequence, a method of making an antibody to gp120, and a method of removing HIV from a bodily fluid.
PCT/US2000/023505 1999-08-27 2000-08-25 POLYPEPTIDES THAT BIND HIV gp120 AND RELATED NUCLEIC ACIDS, ANTIBODIES, COMPOSITIONS, AND METHODS OF USE WO2001016182A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU69410/00A AU6941000A (en) 1999-08-27 2000-08-25 Polypeptides that bind hiv gp120 and related nucleic acids, antibodies, compositions, and methods of use
US10/084,813 US7304127B2 (en) 1999-08-27 2002-02-27 Polypeptides that bind HIV gp120 and related nucleic acids, antibodies, compositions, and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15127099P 1999-08-27 1999-08-27
US60/151,270 1999-08-27

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/084,813 Continuation US7304127B2 (en) 1999-08-27 2002-02-27 Polypeptides that bind HIV gp120 and related nucleic acids, antibodies, compositions, and methods of use

Publications (2)

Publication Number Publication Date
WO2001016182A2 WO2001016182A2 (en) 2001-03-08
WO2001016182A3 true WO2001016182A3 (en) 2002-08-15

Family

ID=22538016

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/023505 WO2001016182A2 (en) 1999-08-27 2000-08-25 POLYPEPTIDES THAT BIND HIV gp120 AND RELATED NUCLEIC ACIDS, ANTIBODIES, COMPOSITIONS, AND METHODS OF USE

Country Status (2)

Country Link
AU (1) AU6941000A (en)
WO (1) WO2001016182A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1460088A1 (en) 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
EP2201024A1 (en) 2007-08-28 2010-06-30 Ramot At Tel Aviv University Peptides inducing a cd4i conformation in hiv gp120 while retaining vacant cd4 binding site
SG190627A1 (en) 2008-03-13 2013-06-28 Biotest Ag Agent for treating disease
MX2010010026A (en) 2008-03-13 2011-03-21 Biotest Ag Agent for treating disease.
CN102202678A (en) 2008-11-04 2011-09-28 安科治疗公司 CXCR4 receptor compounds
WO2010092185A2 (en) 2009-02-16 2010-08-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Scramblase/cd4 interaction inhibitors for the treatment of lentivirus infections
US9155801B2 (en) 2009-05-28 2015-10-13 The United States Government As Represented By The Department Of Veterans Affairs Amino acid sequences which enhance peptide conjugate solubility
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
WO2011106703A2 (en) * 2010-02-26 2011-09-01 Anchor Therapeutics, Inc. Cxcr4 receptor compounds
RU2517084C2 (en) * 2010-08-06 2014-05-27 Олег Ильич Эпштейн Method and means for inhibiting production or enhancing protein p24 elimination
WO2020008083A1 (en) * 2018-07-05 2020-01-09 Consejo Superior De Investigaciones Científicas Therapeutic target in chemokine receptors for the screening of compounds useful for the treatment of pathological processes involving chemokine signaling

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035881A2 (en) * 1996-03-27 1997-10-02 Ng Gordon Y K Receptor and transporter antagonists
WO1997044055A1 (en) * 1996-05-20 1997-11-27 New York University Methods of identifying g-coupled receptors associated with macrophage-trophic hiv, and diagnostic and therapeutic uses thereof
WO1997045543A2 (en) * 1996-05-28 1997-12-04 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health Cc chemokine receptor 5, antibodies thereto, transgenic animals
WO1997047318A1 (en) * 1996-06-14 1997-12-18 Progenics Pharmaceuticals, Inc. Uses of a chemokine receptor for inhibiting hiv-1 infection
WO1998000538A2 (en) * 1996-07-01 1998-01-08 Biosignal Inc. Peptides and peptidomimetic compounds affecting the activity of g-protein-coupled receptors by altering receptor oligomerization
WO1998001757A1 (en) * 1996-07-08 1998-01-15 Cambridge Antibody Technology Limited Labelling and selection of molecules
WO1998015569A1 (en) * 1996-10-09 1998-04-16 Dana-Farber Cancer Institute Gp120 polypeptides having conformational discontinuous chemokine receptor binding sites and methods of inhibiting hiv infection
WO1999043711A1 (en) * 1998-02-27 1999-09-02 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services G protein-coupled receptor antagonists

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035881A2 (en) * 1996-03-27 1997-10-02 Ng Gordon Y K Receptor and transporter antagonists
WO1997044055A1 (en) * 1996-05-20 1997-11-27 New York University Methods of identifying g-coupled receptors associated with macrophage-trophic hiv, and diagnostic and therapeutic uses thereof
WO1997045543A2 (en) * 1996-05-28 1997-12-04 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health Cc chemokine receptor 5, antibodies thereto, transgenic animals
WO1997047318A1 (en) * 1996-06-14 1997-12-18 Progenics Pharmaceuticals, Inc. Uses of a chemokine receptor for inhibiting hiv-1 infection
WO1998000538A2 (en) * 1996-07-01 1998-01-08 Biosignal Inc. Peptides and peptidomimetic compounds affecting the activity of g-protein-coupled receptors by altering receptor oligomerization
WO1998001757A1 (en) * 1996-07-08 1998-01-15 Cambridge Antibody Technology Limited Labelling and selection of molecules
WO1998015569A1 (en) * 1996-10-09 1998-04-16 Dana-Farber Cancer Institute Gp120 polypeptides having conformational discontinuous chemokine receptor binding sites and methods of inhibiting hiv infection
WO1999043711A1 (en) * 1998-02-27 1999-09-02 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services G protein-coupled receptor antagonists

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHAN STEPHEN Y ET AL: "V3 Recombinants indicate a central role for CCR5 as a coreceptor in tissue infection by human immunodeficiency virus type 1.", JOURNAL OF VIROLOGY, vol. 73, no. 3, March 1999 (1999-03-01), pages 2350 - 2358, XP002156131, ISSN: 0022-538X *
FARZAN MICHAEL ET AL: "A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5.", JOURNAL OF VIROLOGY, vol. 72, no. 2, February 1998 (1998-02-01), pages 1160 - 1164, XP002156130, ISSN: 0022-538X *
SHAPIRA-NAHOR O ET AL: "CD4-DERIVED SYNTHETIC PEPTIDE BLOCKS THE BINDING OF HIV-1 GP120 TO CD4-BEARING CELLS AND PREVENTS HIV-1 INFECTION", CELLULAR IMMUNOLOGY,US,SAN DIEGO, CA, vol. 128, 1990, pages 101 - 117, XP002011487 *

Also Published As

Publication number Publication date
WO2001016182A2 (en) 2001-03-08
AU6941000A (en) 2001-03-26

Similar Documents

Publication Publication Date Title
Arnon et al. Chemical and immunological characterization of a unique antigenic region in lysozyme
CA2413857A1 (en) Pd-l2 molecules: pd-1 ligands and uses therefor
WO2001016182A3 (en) POLYPEPTIDES THAT BIND HIV gp120 AND RELATED NUCLEIC ACIDS, ANTIBODIES, COMPOSITIONS, AND METHODS OF USE
ES2121400T3 (en) CELL SELECTION POSITIVE AND POSITIVE / NEGATIVE MEDIATED BY RELEASE WITH PEPTIDES.
JPH02501112A (en) Purification method by immunoaffinity
US6274324B1 (en) Specific binding reagent comprising a variable domain protein linked to a support or tracer
CA2395291A1 (en) Five-helix protein
CA2248140A1 (en) Assay and reagents for quantifying hbnp
ES8601477A1 (en) Immunoassay for nonenzymatically glucosylated proteins and protein fragments - an index of glycemia.
JP2009509535A5 (en)
CA2457414A1 (en) Virus coat protein/receptor chimeras and methods of use
CA2258494A1 (en) Polypeptides capable of forming antigen binding structures with specificity for the rhesus d antigens, the dna encoding them and the process for their preparation and use
AU4422893A (en) Monoclonal antibody against protein C
Keen et al. Identification of the clathrin-binding domain of assembly protein AP-2
CA2393127A1 (en) Diagnostic assay for stroke
WO1999009179A3 (en) Antigen constructs useful in the detection and differentiation of antibodies to hiv
CY1107431T1 (en) PARTICLES FOR GONAL TREATMENT
WO1994026891A3 (en) Purified mammalian flt3 ligands and agonists and antagonists thereof
CA2490538A1 (en) New assays for preimplantation factor and preimplantation factor peptides
AU8220998A (en) Method for isolating a target biological material, capture phase, detecting phase and reagent containing them
JP2003531634A5 (en)
CA2084386A1 (en) Hiv antigen
WO2000052154A3 (en) Methods and reagents for decreasing clinical reaction to allergy
US5310876A (en) Expression of HIV1 and HIV2 polypeptides and their use
WO2006029338A3 (en) Modified hiv-1 envelope proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10084813

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)